BiomX Inc. (AMEX:PHGE) Q4 2022 Earnings Call Transcript

Jonathan Solomon: Sure. So pleasure and good morning. I think as you noted, the data in Part 1 is much more dramatic than we anticipated in an initial study. So we are seeing the effect kind of earlier and a greater magnitude than one would expect. We’re currently proceeding with Part 2 as planned. The team is thinking consulting obviously with the partner, the CF Foundation KOLs to think when there’s any additions, whether there’s anything addition we can learn in Part 2. And I think once that’s formal, if there’s any updates, we’ll provide them, but nothing so far. And then to your question about BX003, as we’ve guided, I think we want to be very conservative. I think we’ve seen kind of the market still not in a good shape.

And so we want to kind of make sure we’re putting all the efforts into the CF program and make sure we got a good handle on the Part 2 and kind of thinking already about pivotal study. After that, once that’s solidified, we see where the market is, I think then we’ll provide guidance on BX003.

Unidentified Analyst: Thank you.

Jonathan Solomon: You bet, pleasure.

Operator: Thank you. There are no further questions at this time. I would now like to hand the call back over to Jonathan Solomon for any closing remarks.

Jonathan Solomon: Sure. So everyone, thank you again for joining us this morning. We look forward to providing you future updates on our clinical program this year. Have a wonderful day, and please feel free to reach out to us with any additional questions. Thanks again.

Operator: Thank you. This does conclude today’s teleconference. We appreciate your participation. You may disconnect your lines at this time. Enjoy the rest of your day.